GLP-1 Biomarkers: Standard & Transcriptomic
A complete guide to the biomarkers that matter during GLP-1 therapy — from the standard blood markers your prescribing provider may order to the advanced transcriptomic signals that reveal what's changing at the molecular level.
Standard Lab Biomarkers
These biomarkers are tracked by traditional lab panels. They provide valuable but retrospective data — showing what has already changed in your body. Your prescribing provider may order these through any clinical laboratory.
Note: One Health Labs does not offer standard blood work. The information below is provided as an educational reference for patients monitoring their GLP-1 therapy.
Metabolic Markers
These biomarkers track how your body processes sugar, fat, and insulin — the core systems GLP-1 medications target.
Fasting Glucose
Normal: 70–99 mg/dL
What it measures: Blood sugar levels after an overnight fast.
Why it matters: GLP-1s improve insulin sensitivity and lower fasting glucose.
Tracking this shows whether your medication is reducing insulin resistance and improving
how efficiently your body uses sugar for energy.
HbA1c
Normal: <5.7%
What it measures: Average blood sugar over the past 2–3 months.
Why it matters: The gold standard for long-term glycemic control. A dropping
HbA1c confirms your GLP-1 therapy is producing sustained metabolic improvements — not just
day-to-day fluctuations.
Fasting Insulin
Normal: 2.6–24.9 µIU/mL
What it measures: Insulin levels after fasting — a direct measure of insulin resistance.
Why it matters: Falling fasting insulin means your body needs less insulin
to control blood sugar. GLP-1s should steadily improve this — if insulin stays high, your
therapy may need adjustment.
HOMA-IR
Optimal: <1.0 | Normal: <2.0
What it measures: Calculated insulin resistance index using fasting glucose and insulin.
Why it matters: HOMA-IR is arguably the single best snapshot of insulin
resistance. A declining score means your GLP-1 is doing its job at the metabolic level — even
before weight loss becomes visible.
Hepatic Markers
Your liver works harder during rapid metabolic change. These markers ensure it's handling the shift safely.
ALT (Alanine Aminotransferase)
Normal: 7–56 U/L
What it measures: An enzyme released when liver cells are damaged.
Why it matters: Rapid weight loss mobilizes fat stored in the liver. While GLP-1s
generally improve fatty liver disease, transient ALT spikes can signal the liver is under stress
during the transition. Monitoring catches this early.
AST (Aspartate Aminotransferase)
Normal: 10–40 U/L
What it measures: Another liver enzyme, also found in heart and muscle tissue.
Why it matters: Paired with ALT, the AST/ALT ratio helps distinguish between liver
stress and muscle-related enzyme release — particularly important since GLP-1 therapy can affect
lean muscle mass.
Lipid, Thyroid & Inflammatory Markers
Cardiovascular risk, thyroid safety, and systemic inflammation — the broader picture of how your body is responding.
Triglycerides
Normal: <150 mg/dL
What it measures: Fat circulating in your bloodstream.
Why it matters: Triglycerides are typically the first lipid marker to improve on
GLP-1 therapy — often dropping within 4–8 weeks. A declining triglyceride level is one of the earliest
traditional signs that your medication is working.
LDL Cholesterol
Optimal: <100 mg/dL
What it measures: "Bad" cholesterol that builds up in artery walls.
Why it matters: GLP-1s have demonstrated cardiovascular benefit in clinical trials.
Tracking LDL confirms whether the lipid-lowering effect is translating to reduced cardiovascular risk
for you specifically.
TSH (Thyroid-Stimulating Hormone)
Normal: 0.4–4.0 mIU/L
What it measures: How hard your thyroid is working.
Why it matters: GLP-1 medications carry an FDA boxed warning for medullary thyroid
carcinoma risk (observed in rodent studies). While human risk remains low, monitoring TSH
is standard clinical practice during GLP-1 therapy, especially for patients with thyroid history.
hs-CRP (High-Sensitivity C-Reactive Protein)
Low risk: <1.0 mg/L
What it measures: Systemic inflammation levels.
Why it matters: Chronic inflammation drives metabolic disease and cardiovascular risk.
GLP-1s have anti-inflammatory properties — a falling hs-CRP confirms these benefits are active.
Persistently elevated hs-CRP may signal that inflammation isn't responding to therapy.
OHL's Transcriptomic Biomarkers
These are the molecular signals that One Health Labs measures through our proprietary transcriptomic testing. Unlike standard blood markers, these are leading indicators — revealing what is actively changing at the cellular level.
Metabolic Pathway mRNA Panel
Leading Indicator
What it measures: Active gene expression across fat metabolism,
insulin signaling, and energy production pathways.
Why it matters on GLP-1: Your blood work might look unchanged at 4 weeks — but mRNA
can reveal whether lipogenesis (fat storage) genes are being suppressed, whether insulin receptor
signaling is improving, and whether mitochondrial biogenesis is ramping up. These molecular shifts
happen weeks before blood markers move.
What to watch for: Rising expression of fatty acid oxidation genes (like CPT1A)
alongside suppression of lipogenesis genes indicates your therapy is actively shifting metabolism
toward fat burning.
Catabolic Gene Expression
Leading Indicator
What it measures: Muscle protein breakdown genes — specifically
MURF1 (TRIM63), MAFbx/Atrogin-1, and FOXO transcription factors.
Why it matters on GLP-1: One of the biggest concerns with GLP-1 therapy is losing
muscle along with fat. By the time you notice weakness or see it on a DEXA scan, significant
lean mass has already been lost. Catabolic mRNA markers detect muscle breakdown within 14 days —
early enough to intervene with exercise protocols or therapy adjustments.
What to watch for: Elevated MURF1 or MAFbx expression signals active
muscle protein breakdown — a prompt to add resistance training or adjust dosing timing.
Receptor Binding Confirmation
Leading Indicator
What it measures: mRNA markers that confirm whether GLP-1 receptors
(GIPR, GLP1R) are actively engaging with your medication.
Why it matters on GLP-1: Not every patient responds equally to GLP-1 therapy.
Receptor expression varies between individuals and can change over time. Confirming that the
target receptors are actively transcribed means your medication has functioning targets to bind
to — a prerequisite for therapeutic effect.
What to watch for: Low or declining GLP1R/GIPR expression may
indicate reduced receptor availability, which could explain a plateau in therapy response
and signal the need for clinical reassessment.
Inflammatory Cytokine Response
Leading Indicator
What it measures: Gene expression profiling of inflammatory pathways,
including cytokine signaling genes (TNF-α, IL-6, NF-κB pathway components) and anti-inflammatory
mediators.
Why it matters on GLP-1: While hs-CRP gives a single-point snapshot
of inflammation, transcriptomic profiling reveals which inflammatory pathways are active
and whether your therapy is modulating systemic inflammation at the gene expression level. This
provides a far more granular picture than any single blood marker can.
What to watch for: Decreasing pro-inflammatory gene expression
(TNF-α, IL-6) alongside stable or rising anti-inflammatory markers confirms that GLP-1 therapy
is producing real immunomodulatory benefits — not just lowering a single protein level.
Transcriptomic Drift Detection
Leading Indicator · Annual Surveillance
What it measures: Annual surveillance markers that track
longitudinal shifts in your gene expression profile, detecting early molecular signals
of therapy losing effectiveness.
Why it matters on GLP-1: Therapy adaptation is a real concern
for long-term GLP-1 patients. Weight regain or metabolic plateau often takes months to manifest
on a scale or in blood work. Transcriptomic drift detection identifies the earliest molecular
signals — subtle shifts in metabolic and receptor gene expression — before physical weight regain
occurs, giving you and your provider a critical window to adjust.
What to watch for: Gradual reversion of previously improved
gene expression patterns (e.g., rising lipogenesis markers, declining receptor expression)
is an early warning that therapeutic efficacy may be waning.
Lagging vs. Leading Indicators
Standard lab markers tell you what your body did over the past weeks and months. Transcriptomic markers tell you what your body is doing right now. Both play a role in comprehensive GLP-1 monitoring.
| Standard Labs | OHL Transcriptomic Profiling | |
|---|---|---|
| Timing | Reflects past weeks/months | Reflects current molecular activity |
| Indicator Type | Lagging | Leading |
| Detects Response | After 8–12+ weeks | Within days to weeks |
| Muscle Loss | Visible on DEXA after months | Catabolic genes detectable in 14 days |
| Scope | Individual analytes (proteins, enzymes) | Pathway-level gene expression profiling |
| Available From | Any clinical laboratory | One Health Labs |
Know Your Numbers.
Know Your Molecules.
Standard labs show what changed. Transcriptomic profiling shows what's changing. Together, they give you the complete picture of your GLP-1 response.